SPIA
SPRY icon

Steward Partners Investment Advisory’s ARS Pharmaceuticals SPRY Stock Holding History

Steward Partners Investment Advisory’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Sell
146,453
-69,843
-32% -$669K 0.01% 1074
2025
Q4 		$2.52M Buy
216,296
+69,604
+47% +$677K 0.01% 696
2025
Q3 		$1.47M Buy
146,692
+18,512
+14% +$266K 0.01% 895
2025
Q2 		$2.24M Buy
128,180
+79,700
+164% +$1.15M 0.02% 684
2025
Q1 		$610K Buy
48,480
+10,430
+27% +$125K 0.01% 1132
2024
Q4 		$401K Buy
38,050
+12,200
+47% +$171K ﹤0.01% 1265
2024
Q3 		$375K Buy
25,850
+24,650
+2,054% +$293K ﹤0.01% 1237
2024
Q2 		$10.2K Sell
1,200
-100
-8% -$887 ﹤0.01% 2814
2024
Q1 		$13.3K Hold
1,300
– – ﹤0.01% 2699
2023
Q4 		$7.12K Hold
1,300
– – ﹤0.01% 2832
2023
Q3 		$4.91K Hold
1,300
– – ﹤0.01% 2835
2023
Q2 		$8.71K Buy
1,300
+100
+8% +$667 ﹤0.01% 2618
2023
Q1 		$7.81K Buy
+1,200
New +$9.22K ﹤0.01% 2634

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Steward Partners Investment Advisory's SPRY Position: Q1 2026 in Review

Steward Partners Investment Advisory reduced its ARS Pharmaceuticals (SPRY) stake by 32% in Q1 2026, selling an estimated $669K and leaving 146,453 shares worth $1.18M. The position accounts for 0.01% of the portfolio, ranked #1074.

Steward Partners Investment Advisory first reported a position in SPRY in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.52M in Q4 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Steward Partners Investment Advisory held 146,453 shares of ARS Pharmaceuticals worth $1.18M as of Q1 2026.
  • Steward Partners Investment Advisory sold 69,843 ARS Pharmaceuticals shares in Q1 2026, an estimated $669K.
  • ARS Pharmaceuticals made up 0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #1074 holding.
  • Steward Partners Investment Advisory first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Steward Partners Investment Advisory's ARS Pharmaceuticals position peaked at $2.52M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.